BioSpace News Archive

Drug Development

On the Heels of $46.7 Million Financing, Glympse Bio Announces Positive Data for NASH Sensors

Glympse Bio’s novel injectable mixture of synthetic sensors, which quantify protease activity and predict treatment response in non-alcoholic steatohepatitis (NASH), was demonstrated as safe and well-tolerated in healthy volunteers in a gene expression study of advanced fibrosis.

November 16, 2020
·
3 min read
·
Brandon May
Drug Development

Gilead and Novo Nordisk’s Triple-Combo Shows Promise for Untapped NASH Market

Gilead Sciences and Novo Nordisk presented data from a Phase II proof-of-concept clinical trial of semaglutide in combinations with cilofexor and/or firsocostat in non-alcoholic steatohepatitis.

November 16, 2020
·
4 min read
·
Mark Terry
Drug Development

Moderna’s COVID-19 Vaccine Interim Readout Suggests 94.5% Efficacy

Only a week after Pfizer and BioNTech’s preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, Moderna reported interim efficacy data for its vaccine of 94.5%.

November 16, 2020
·
4 min read
·
Mark Terry
Business

Mouse Seeking Elephant: Innovators Address Unmet Needs in Biotech and Analytics

The 2020 Virtual Texas Life Science Forum, sponsored by BioHouston November 10-12, showcased dozens of innovative, early stage companies seeking partners to reach the next level.

November 16, 2020
·
5 min read
·
Gail Dutton
Policy

J&J Secures Additional $1 Billion in Funding for COVID-19 Vaccine

Johnson & Johnson secured more than $1 billion in additional funding for its COVID-19 vaccine research through an expansion of its partnership with the Biomedical Advanced Research and Development Authority.

November 16, 2020
·
3 min read
·
Alex Keown
Drug Development

FDA CRL Delays Sanofi’s Hopes of Approval for First CAD Treatment Sutimlimab

Late Friday, the regulatory agency rejected the medication of sutimlimab due to deficiencies from a pre-license inspection of a third-party manufacturing facility.

November 16, 2020
·
2 min read
·
Alex Keown
Deals

Sumitovant to Snap Up Development Partner Urovant Sciences

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma.

November 16, 2020
·
2 min read
·
Heather McKenzie
Drug Development

Albireo Pharma Eyes Potential Approval for First PFIC Treatment

On Friday, the Boston-based company presented positive Phase III data in progressive familial intrahepatic cholestasis (PFIC) at the American Association for the Study of Liver Diseases’ annual meeting.

November 16, 2020
·
4 min read
·
Alex Keown
Policy

Biopharma Update on the Novel Coronavirus: November 17

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.

November 16, 2020
·
6 min read
·
BioSpace Editorial Staff
Business

Retrophin Switches Name to Travere Therapeutics in Reflection of Evolving Pipeline

Travere Therapeutics will also begin trading under the new ticker symbol, “TVTX” on the Nasdaq Global Select Market beginning on Nov. 19.

November 16, 2020
·
3 min read
·
Krystle Vermes